The European Commission has approved Johnson & Johnson's chemotherapy-free combination of Rybrevant, or amivantamab, and Lazcluze, or lazertinib, for first-line treatment of advanced non-small cell lung cancer with specific EGFR mutations. The approval is based on the MARIPOSA study, which showed a 30% reduction in disease progression or death compared to Tagrisso.